Our recent recommended top pick from Healthcare sector: PFE: released better than expected financial results; raised full year guidance;
The company’s earnings per share (EPS) in the second quarter stood at $0.60, surpassing the consensus estimate of $0.46. Revenue came in at $13.3 billion, also above the projected $13.03 billion.
Pfizer reported adjusted research and development expenses of $2.67 billion for the period, compared to the estimated $2.83 billion.
Looking forward, the pharmaceutical giant now projects FY2024 EPS of $2.45 to $2.65, up from the previous guidance of $2.15 to $2.35, and above the consensus estimate of $2.38.
The company’s earnings per share (EPS) in the second quarter stood at $0.60, surpassing the consensus estimate of $0.46. Revenue came in at $13.3 billion, also above the projected $13.03 billion.
Pfizer reported adjusted research and development expenses of $2.67 billion for the period, compared to the estimated $2.83 billion.
Looking forward, the pharmaceutical giant now projects FY2024 EPS of $2.45 to $2.65, up from the previous guidance of $2.15 to $2.35, and above the consensus estimate of $2.38.
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.